반려동물 통증 관리 시장 : 시장 기회, 성장 촉진요인, 산업 동향 분석, 예측(2025-2034년)

The global companion animal pain management market was valued at USD 1.9 billion in 2024 and is estimated to grow at a CAGR of 6.2% to reach USD 3.4 billion by 2034. This steady growth is fueled by the increasing incidence of chronic conditions in pets, which has led to a greater demand for effective pain relief solutions. Alongside this, technological progress in veterinary therapeutics and the rising number of dedicated pain management facilities are contributing significantly to market expansion. As companion animals live longer due to improved veterinary care, conditions such as osteoarthritis, post-surgical discomfort, and cancer-related pain are becoming more prevalent, creating a higher need for accessible and efficient pain management tools. The industry encompasses a wide range of pharmaceutical products such as NSAIDs, opioids, and anesthetics, as well as medical devices aimed at alleviating both acute and chronic pain in animals like dogs, cats, horses, and others.

Between 2021 and 2023, the market displayed consistent year-over-year growth, increasing from USD 1.6 billion in 2021 to USD 1.7 billion in 2022 and reaching USD 1.8 billion by 2023. This upward trend indicates an increasing awareness among pet owners and veterinarians about the importance of managing pain in animals to enhance their quality of life. Furthermore, the introduction of advanced drug formulations, including extended-release and flavored oral medications, has made it easier for both pet owners and veterinary professionals to administer pain relief, further boosting adoption rates. The development of innovative drug delivery systems, such as transdermal patches, has also played a critical role in simplifying treatment protocols and improving patient outcomes.

By animal type, dogs held the dominant market position in 2024, generating USD 1.1 billion in revenue and expected to grow to USD 1.9 billion by 2034 at a CAGR of 6.1%. This is largely due to the high dog population and the greater prevalence of orthopedic and chronic conditions in this group, which significantly contribute to the demand for pain relief therapies.

In terms of product type, the market is segmented into drugs and devices. The drugs segment led the global market in 2024, capturing 81.7% of the total share, and is anticipated to grow at a CAGR of 6% over the forecast period. Drugs remain the first-line treatment for veterinarians due to their rapid onset and effectiveness in managing a wide range of pain conditions. This segment includes NSAIDs, opioids, anesthetics, and other drug classes. The continuous enhancement in pharmaceutical innovation, such as long-acting formulations and easier-to-administer medications, supports the growing preference for drug-based treatments in veterinary care.

Based on application, the market is divided into osteoarthritis and joint pain, cancer, postoperative pain, and other uses. The osteoarthritis and joint pain segment garnered a valuation of USD 807.2 million in 2024 and is forecasted to grow at a CAGR of 6.4% between 2025 and 2034. The rise in age-related joint disorders among pets, particularly dogs and cats, is a key factor in this segment's expansion. Veterinary professionals are now able to diagnose joint problems earlier, thanks to advancements in diagnostic technologies such as radiography, gait analysis, and mobility tracking tools, leading to a surge in treatment rates and driving the demand for pain management solutions.

The companion animal pain management market in the United States was valued at USD 795.7 million in 2024, growing from USD 754.2 million in 2023. The country is poised to expand at a CAGR of 5.9% during the forecast period. Several factors underpin this growth, including the high occurrence of musculoskeletal issues in pets, the increasing rate of pet ownership, and access to advanced veterinary care infrastructure. More pet owners are prioritizing the well-being of their animals, which is reflected in the greater adoption of modern pain relief options, including regenerative medicine and alternative therapies. The availability of insurance plans that cover various pain treatments has further improved access to care.

Around 45% of the global market share is held by the top five companies. This competitive landscape includes several prominent players offering advanced pain relief solutions tailored for conditions like musculoskeletal pain, hip dysplasia, and arthritis. These companies maintain their market positions through extensive product offerings, well-established brand presence, and wide-reaching distribution channels. Their focus on research and development, coupled with a growing emphasis on innovation, continues to shape the future of pain management for companion animals.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Growing pet ownership and humanization of pets
    • 3.2.1.2 Rising cases of arthritis and chronic pain in aging pets
    • 3.2.1.3 Advances in pain management drugs and devices
    • 3.2.1.4 Increasing expenditure on veterinary healthcare
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of veterinary pain management treatments
    • 3.2.2.2 Strict regulatory approvals for pain management drugs
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Future trends
• 3.6 Regulatory landscape
• 3.7 Trump administration tariffs
  • 3.7.1 Impact on trade
    • 3.7.1.1 Trade volume disruptions
    • 3.7.1.2 Retaliatory measures
  • 3.7.2 Impact on the Industry
    • 3.7.2.1 Supply-side impact (raw materials)
      • 3.7.2.1.1 Price volatility in key materials
      • 3.7.2.1.2 Supply chain restructuring
      • 3.7.2.1.3 Production cost implications
    • 3.7.2.2 Demand-side impact (selling price)
      • 3.7.2.2.1 Price transmission to end markets
      • 3.7.2.2.2 Market share dynamics
      • 3.7.2.2.3 Consumer response patterns
  • 3.7.3 Key companies impacted
  • 3.7.4 Strategic industry responses
    • 3.7.4.1 Supply chain reconfiguration
    • 3.7.4.2 Pricing and product strategies
    • 3.7.4.3 Policy engagement
  • 3.7.5 Outlook and future considerations
• 3.8 Porter's analysis
• 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Animal Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Dogs
• 5.3 Cats
• 5.4 Horses
• 5.5 Other animal types

Chapter 6 Market Estimates and Forecast, By Product Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Drugs
  • 6.2.1 Type
    • 6.2.1.1 Non-steroidal anti-inflammatory drugs (NSAIDS)
    • 6.2.1.2 Opioids
    • 6.2.1.3 Anesthetics
    • 6.2.1.4 Other drug types
  • 6.2.2 Route of administration
    • 6.2.2.1 Oral
    • 6.2.2.2 Parenteral
    • 6.2.2.3 Topical
  • 6.2.3 Distribution channel
    • 6.2.3.1 Veterinary hospitals pharmacies
    • 6.2.3.2 Retail pharmacies
    • 6.2.3.3 Online pharmacies
• 6.3 Devices
  • 6.3.1 Laser therapy
  • 6.3.2 Electromagnetic therapy

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Osteoarthritis & joint pain
• 7.3 Cancer
• 7.4 Postoperative pain
• 7.5 Other applications

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Argentina
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE

Chapter 9 Company Profiles

• 9.1 Aurora Pharmaceutical
• 9.2 Bimeda
• 9.3 Boehringer Ingelheim
• 9.4 Ceva Sante Animale
• 9.5 Chanelle Pharma
• 9.6 Companion Animal Health
• 9.7 Dechra Pharmaceuticals
• 9.8 Elanco
• 9.9 INDIBA
• 9.10 Merck
• 9.11 Norbrook
• 9.12 PainTrace
• 9.13 Vetaquinol
• 9.14 Vetnation Pharma
• 9.15 Virbac
• 9.16 Zoetis